Acurx Pharmaceuticals Unveils Year-End and Q4 Financial Update with Promising Developments

Acurx Pharmaceuticals Reports Year-End and Q4 Results

On March 13, 2026, Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) shared its financial and operational results for both the entire year and the fourth quarter ended December 31, 2025. The Staten Island-based biopharmaceutical company is currently developing a new class of antibiotics aimed at addressing difficult-to-treat bacterial infections, focusing particularly on Clostridioides difficile infection (CDI).

Key Highlights from Q4 2025

The fourth quarter of 2025 brought several noteworthy occurrences: First, in October, Acurx raised approximately $1.4 million from the exercise of 170,068 Series F Warrants. This move was accompanied by a significant presentation at IDWeek in Atlanta, where Dr. Michael Silverman, the Medical Director of Acurx, alongside Dr. Kevin Garey of the University of Houston, discussed the latest updates on their lead antibiotic candidate, ibezapolstat, and its exciting microbiome-sparing properties. This presentation also unveiled new data from a sophisticated mouse infection model, indicating potential benefits of their DNA pol IIIC inhibitor pipeline.

In another milestone, results from a collaboration with Leiden University Medical Center were published in Nature Communications in November 2025, detailing the structural biology of ibezapolstat. This publication represents a significant advancement in the understanding of this unique compound, which is targeted toward Gram-positive bacteria. With the exciting backdrop of scientific progress, Acurx also secured a new patent for their Pol IIIC inhibitors in February 2026, covering both compositions and usage extending through December 2039.

March 9, 2026 marked another pivotal moment with the announcement of a remarkable ibezapolstat clinical trial program designed for patients suffering from recurrent CDI. This trial aims to transform conventional treatment frameworks, shifting from a dual-agent approach to a single agent. Previous Phase 2 trials highlighted ibezapolstat's 96% clinical success in treating acute CDI without recurrence, raising hopes for its potential to alter the landscape of treatment for recurrent CDI.

Financial Overview of 2025

Examining the financial landscape, Acurx completed the year with a cash position of $7.6 million, a significant increase from $3.7 million the previous year. The fourth quarter alone witnessed gross proceeds approximating $1.5 million through equity financing activities, adding up to around $4.0 million for the whole year. Research and development expenses were notably reduced to $1.8 million for the year, down from $5.4 million in 2024, owing primarily to decreased manufacturing and consulting expenses.

General and administrative expenses reflected a similar trend, dropping to $6.3 million, which was considerably less than the previous year's $8.7 million. These financial efficiencies led to a net loss of $1.6 million or $0.73 per diluted share for the fourth quarter, a much-improved position compared to the $2.8 million loss during the same quarter last year. Over the year, the overall net loss decreased to $8.0 million from $14.1 million in 2024, showcasing the company's commitment to enhancing its financial health amid ongoing development efforts.

Future Directions

As Acurx navigates the regulatory landscape, the company expressed optimism regarding the FDA's recent announcement in the New England Journal of Medicine, suggesting a potential shift in trial requirements from two to one for registration processes. This change could significantly impact Acurx's clinical development strategy, especially for its broader CDI patient program. Looking ahead, Acurx Pharmaceuticals is in a strong position to move forward with its innovative clinical research in the pursuit of significantly improving patient outcomes for those battling recurrent CDI.

For more information, please visit Acurx Pharmaceuticals.